RBC Capital Downgrades PDL BioPharma (PDLI) to Sector Perform, Maintains Price Target

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/20/2026

1. TGT
2. SPY
3. EL
4. BILL
5. ADI
6. MRK
7. MRNA
8. TJX
9. DE
10. LOW

October 11, 2011 7:40 AM EDT
Get Alerts PDLI Hot Sheet
Price: $2.47 --0%

Rating Summary:
    2 Buy, 3 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 10 | Down: 12 | New: 19
Join SI Premium – FREE
RBC Capital downgraded shares of PDL BioPharma (NASDAQ: PDLI) to a Sector Perform rating from its previous rating of Outperform. The firm reaffirmed its price target of $6.00.

For more ratings news on PDL BioPharma click here and for the rating history of PDL BioPharma click here.

Shares of PDL BioPharma closed at $5.70 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Downgrades

Related Entities

RBC Capital